Horizon Space Acquisition II Corp. Schedules Vote to Extend Merger Deadline Amid SL Bio Deal Uncertainty

summarizeSummary

Horizon Space Acquisition II Corp. filed a definitive proxy statement for an extraordinary general meeting on February 13, 2026, seeking shareholder approval to extend its business combination deadline by up to 12 months to February 18, 2027, citing uncertainty about completing its proposed merger with SL Bio Ltd. by the current deadline.

check_boxKey Events

• Shareholder Meeting Scheduled

  An Extraordinary General Meeting is set for February 13, 2026, to vote on amending the company's organizational documents and trust agreement to extend the business combination deadline.

• Extension Proposals

  Shareholders will vote on proposals to allow up to 12 one-month extensions, pushing the business combination deadline to February 18, 2027, with the sponsor depositing monthly extension fees.

• Uncertainty for SL Bio Merger

  The Board is "not certain" it can complete the proposed de-SPAC merger with SL Bio Ltd. by the current February 18, 2026, deadline, necessitating the extension.

• Redemption Option for Public Shareholders

  Public shareholders can redeem their shares for approximately $10.53 per share from the trust account if the extension is approved, regardless of their vote.

auto_awesomeAnalysis

This definitive proxy statement confirms the critical shareholder vote for Horizon Space Acquisition II Corp. to extend its deadline for completing a business combination. The company explicitly states it is "not certain" whether it will have sufficient time to complete its proposed merger with SL Bio Ltd. by the current February 18, 2026, deadline. Approval of the extension proposals would allow the SPAC to extend its operational period by up to twelve additional months, to February 18, 2027, with the sponsor depositing monthly extension fees. This filing follows previous disclosures about the postponement of the de-SPAC merger meeting and a preliminary proxy for these amendments. The need for an extension, coupled with uncertainty regarding the existing merger, signals potential challenges in closing the deal and could lead to significant redemptions by public shareholders, although the current stock price is above the stated redemption value from the trust account. If the extension is not approved, the company faces liquidation.